Barcelona, Spain, Thursday 14 June 2007: 36% of patients with refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Overactive B-cells are commonly found in patients with SLE and reducing the number of B-cells in the system by BCDT has been suggested as a promising therapy for SLE patients who are unresponsive to other treatments.
In this study, initiated in 2000, patients with refractory SLE were treated with BCDT (based on rituximab) using a combination protocol with cyclophosphamide and steroids. Of the 33 patients who had a minimum of 6 months follow-up duration at the time of analysis (mean duration 37 months, range 6-79), 12 patients remained well. Median duration of B-cell depletion was 4 months (range 2-15), with 2 patients remaining depleted at time of analysis (73 and 8 months respectively). B-cell depletion was beneficial clinically, with a decrease of median global BILAG scores (clinical activity index – see Editors note) from 13 to 5 when measured between 5 and 8 months p<0.0001).
Autoantibody profiling was also examined during the study as a possible predictor of flare of disease. Patients with low baseline serum C3 (84%) had a shorter time to flare post-BCDT (a lower level is a strong indicator of high levels of disease activity) and patients with anti-ENA antibodies notably anti-Sm antibodies (63%) were more likely to flare at any time after BCDT with an odds ratio (OR) of 6 (p=0.03).
Co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom, commented: “Although double blind trials are awaited, our results are encouraging. They show that B-cell depletion therapy is a promising therapeutic option for lupus patients who have a historically difficult to treat disease, and potentially could minimise the need for continuous immunosuppressive therapy. Through monitoring the autoantibody profile of these patients we have seen a strong association with disease activity post-BCDT, offering us valuable insight for future patient identification strategies.”
Of the 20 patients who experienced flares after receiving BCDT, 11 flared between 6-12 months post-BCDT, with a mean time to flare (TTF) of 10 months post-BCDT. Thirteen patients have been retreated with at least another cycle of rituximab. In terms of B-cell depletion, one patient in the study sample did not deplete at all.
The study concludes that the long term safety profile of B-cell depletion therapy is so far favourable, though ongoing vigilance is recommended. Serious adverse events included reports of pneumococcal sepsis, severe serum sickness reaction and seizure related to hyponatriaemia. Two patient deaths occurred during the follow up assessment period.
Note to Editors:
Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that is potentially debilitating and sometimes fatal as the immune system attacks the body’s cells and tissue, resulting in inflammation and tissue damage. The course of the disease is unpredictable, with periods of illness (called flares) alternating with periods of inactivity (remission). SLE is found most commonly in women.
BILAG
The BILAG index is a clinical measure of SLE disease activity. A flare of active SLE in this study was defined as a new BILAG A or two new BILAG B scores in any organ system. An increase in BILAG score represents an increase in symptom severity or worsening symptoms.
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:
Email: eularpressoffice@uk.cohnwolfe.com
Rory Berrie: Onsite tel: +44 (0) 7900 698 946
Camilla Dormer: Onsite tel: +44 (0) 7725 328 983
Abstract number: OPO020
About EULAR
- The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations.
- The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the governing bodies in Europe.
- Diseases of bones and joints, such as rheumatoid arthritis and osteoarthritis cause disability in 4 - 5 % of the adult population and are predicted to rise as people live longer.
- As new treatments emerge and cellular mechanisms are discovered, the 8th Annual European Congress of Rheumatology in Barcelona (EULAR 2007) brings together more than 10,000 experts - scientists, clinicians, healthcare workers, pharmaceutical companies and patients - to share their knowledge in a global endeavour to challenge the pain and disability caused by musculo-skeletal disorders.
- To find out more information about the activities of EULAR, visit: www.eular.org